Abstract
Cancer stem cells or tumour-propagating cells (TPCs) have been identified for a number of cancers, but data pertaining to their existence in lymphoma so far remain elusive. We show for the first time that a small subset of cells purified from human anaplastic lymphoma kinase (ALK)-positive and-negative, anaplastic large cell lymphoma cell lines and primary patient tumours using the side population (SP) technique have serial tumour-propagating capacity both in vitro and in vivo; they give rise to both themselves and the bulk tumour population as well as supporting growth of the latter through the production of soluble factors. In vivo serial dilution assays utilising a variety of model systems inclusive of human cell lines, primary human tumours and nucleophosmin (NPM)-ALK-induced murine tumours demonstrate the TPC frequency to vary from as many as 1/54 to 1/1336 tumour cells. In addition, the SP cells express higher levels of pluripotency-associated transcription factors and are enriched for a gene expression profile consistent with early thymic progenitors. Finally, our data show that the SP cells express higher levels of the NPM-ALK oncogene and are sensitive to an ALK inhibitor.
Original language | English |
---|---|
Pages (from-to) | 1843-1852 |
Number of pages | 10 |
Journal | Oncogene |
Volume | 34 |
Issue number | 14 |
DOIs | |
Publication status | Published - 12 May 2014 |
Bibliographical note
Funding Information:We thank past and present members of the 'Turner lab' for their helpful discussions and critical appraisal of the manuscript. We are grateful to N Miller of the Department of Pathology, University of Cambridge, FACS facility for his assistance with SP analysis and to S Johnson of the Biological Services Unit. We are also indebted to R Jarrett, L Shield and S Crae at the Leukaemia and Lymphoma Research Virus Centre, University of Glasgow, UK, for the provision of primary disaggregated, viable patient material. We also acknowledge the support of the Sam Foye Fund and dedicate this research to the memory of Sam. SDT is a Leukaemia and Lymphoma Research Bennett Fellow (grant numbers 07006, 11051, 12065). NM receives support from the Cambridge Commonwealth Trust, University of Karachi, Pakistan, and the Elimination of Leukaemia Fund. TM is supported by a Leukaemia and Lymphoma Research Gordon Piller Studentship (Grant Number 08064).
Publisher Copyright:
© 2015 Macmillan Publishers Limited.
ASJC Scopus subject areas
- Molecular Biology
- Genetics
- Cancer Research